HKSE - Delayed Quote HKD

TOT BIOPHARM International Company Limited (1875.HK)

1.680 +0.100 (+6.33%)
At close: April 26 at 2:01 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
588,222.000
442,178.000
76,325.000
22,491.000
Cost of Revenue
126,145.000
71,563.000
48,851.000
6,961.000
Gross Profit
462,077.000
370,615.000
27,474.000
15,530.000
Operating Expense
509,942.000
409,449.000
282,928.000
305,268.000
Operating Income
-47,865.000
-38,834.000
-255,454.000
-289,738.000
Net Non Operating Interest Income Expense
-2,317.000
-4,337.000
-1,499.000
174.000
Pretax Income
-49,484.000
-50,046.000
-261,216.000
-288,498.000
Tax Provision
1.000
--
--
--
Net Income Common Stockholders
-49,355.000
-49,916.000
-261,216.000
-288,498.000
Diluted NI Available to Com Stockholders
-49,355.000
-49,916.000
-261,216.000
-288,498.000
Basic EPS
-0.07
-0.08
-0.46
-0.51
Diluted EPS
-0.07
-0.08
-0.46
-0.51
Basic Average Shares
714,307.000
639,307.000
573,360.000
570,334.000
Diluted Average Shares
714,307.000
639,307.000
573,360.000
570,334.000
Total Operating Income as Reported
-46,704.000
-39,076.000
-259,700.000
-288,672.000
Total Expenses
636,087.000
481,012.000
331,779.000
312,229.000
Net Income from Continuing & Discontinued Operation
-49,355.000
-49,916.000
-261,216.000
-288,498.000
Normalized Income
-48,874.250
-47,872.000
-255,464.000
-288,846.000
Interest Income
3,128.000
2,265.000
969.000
1,880.000
Interest Expense
5,445.000
6,602.000
2,468.000
1,706.000
Net Interest Income
-2,317.000
-4,337.000
-1,499.000
174.000
EBIT
-44,039.000
-43,444.000
-258,748.000
-286,792.000
EBITDA
-44,039.000
-5,405.000
-224,511.000
-254,710.000
Reconciled Cost of Revenue
126,145.000
71,563.000
48,851.000
6,961.000
Reconciled Depreciation
27,351.000
38,039.000
34,237.000
32,082.000
Net Income from Continuing Operation Net Minority Interest
-49,355.000
-49,916.000
-261,216.000
-288,498.000
Total Unusual Items Excluding Goodwill
-641.000
-2,044.000
-5,752.000
348.000
Total Unusual Items
-641.000
-2,044.000
-5,752.000
348.000
Normalized EBITDA
-43,398.000
-3,361.000
-218,759.000
-255,058.000
Tax Rate for Calcs
0.000
--
--
--
Tax Effect of Unusual Items
-160.250
--
--
--
12/31/2020 - 11/8/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

6662.TWO BioLASCO Taiwan Co., Ltd.
35.65
-0.42%
 
6733.TWO BioGend Therapeutics Co., Ltd.
36.60
+1.10%
 
6875.TWO Pharmosa Biopharm Inc.
64.50
-1.23%
 
6535.TWO Lumosa Therapeutics Co., Ltd.
172.00
+0.29%
 
6712.TWO Ever Supreme Bio Technology Co., Ltd
207.00
-2.13%
 
6949.TW PELL Bio-Med Technology Co. Ltd.
173.00
+9.84%
 
4726.TWO Mycenax Biotech Inc.
43.85
-4.67%